Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 2Active not recruiting 2Terminated 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 1Muscle Weakness 1

Interventions

Cyclophosphamide 1499Cisplatin 1435Paclitaxel 1340Radiotherapy 1310Carboplatin 1267Gemcitabine 1226Docetaxel 1133Bevacizumab 1070Fluorouracil 906Doxorubicin 805Dexamethasone 755Rituximab 744Capecitabine 735Oxaliplatin 709pembrolizumab 700Etoposide 679Irinotecan 639Filgrastim 624Cytarabine 587Nivolumab 586Leucovorin 583Vincristine 517Cetuximab 479Prednisone 478Bortezomib 474Trastuzumab 468Erlotinib Hydrochloride 467Surveys and Questionnaires 460Methotrexate 444Lenalidomide 436

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × nicotinamide-beta-riboside × Clear all
NCT03789175 2020-12-08

Nicotinamide Riboside on Mitochondrial Function in Li-Fraumeni Syndrome

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
1 enrolled 7 charts

Neoplasms, Muscle Weakness

Data powered by HemOnc (CC BY 4.0) Colophon âš¡